Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Other

Briacell Therapeutics has success with Bria-OTS patient

By The Northwire Desk — AI Analysis Jan 13, 2026 · 17:36 BCT · 15.22 Briacell Therapeutics Corp
BCT · Price

Executive Summary

  • Briacell Therapeutics reports an 11-month sustained complete resolution of a lung metastasis in a 78-year-old HR+/HER2- metastatic breast cancer patient treated with single-agent Bria-OTS.
  • The patient received 17 cycles of therapy, completed 12 months of the study, and remains in survival follow-up with no treatment-limiting toxicities reported.
  • The Phase 1 dose escalation portion of the trial is complete, and the Phase 2a portion evaluating Bria-OTS in combination with an immune checkpoint inhibitor is now underway.

Key Details

  • Patient Profile: 78-year-old woman with advanced metastatic breast cancer (HR+, HER2-), multiple prior treatment failures.
  • Treatment Regimen: Bria-OTS (personalized off-the-shelf immunotherapy) administered as a single agent.
  • Clinical Response: Complete (100%) resolution of a lung metastasis, initially observed at 2 months, confirmed at 4 months, 6 months, and sustained through 11 months.
  • Dosing & Follow-up: Patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up.
  • Safety Profile: No treatment-limiting toxicities reported to date.
  • Study Progression: Phase 1 dose escalation complete; Phase 2a portion (evaluating combination with an immune checkpoint inhibitor) currently active.
  • Trial Identifier: ClinicalTrials.gov NCT06471673.
  • Trial Design: Encompasses monotherapy dose escalation and checkpoint inhibitor combination dose expansion cohorts; company has recently entered the dose expansion phase.

Notable Quotes

  • Neal S. Chawla, MD (Principal Investigator): "The sustained clinical response observed in this late-stage MBC patient, who had previously progressed through multiple prior treatments is remarkable... We are excited to further evaluate Bria-OTS in combination with an immune checkpoint inhibitor in metastatic breast cancer."
  • Dr. William V. Williams (President & CEO): "These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform... Our team remains committed to advancing our novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options."
Read the original news release →

More from Briacell Therapeutics Corp

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other